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Human African trypanosomiasis is a neglected tropical disease caused by Trypanosoma brucei parasites. 
These protists are unable to produce the purine ring, making them vulnerable to the effects of purine 
nucleoside analogues. Starting from 3’-deoxytubercidin 5, a lead compound with activity against central 
nervous stage human African trypanosomiasis, we investigate the structure-activity relationship of the 
purine and ribofuranose ring. The purine ring tolerated only modifications at C7, while from the many 
alterations of the 3’-deoxyribofuranosyl moiety only the arabino analogue 48 showed pronounced 
antitrypanosomal activity. Profiling of the most potent analogues against resistant T. brucei strains 
(resistant to pentamidine, diminazene and isometamidium) showed reduced dependence on uptake 
mediated by the P2 aminopurine transporter compared to 5. The introduction of a 7-substituent confers 
increased affinity for the P1 nucleoside transporter up to 10-fold, while generally retaining high affinity 
for P2. Four of the most promising analogues were found to be metabolically stable, earmarking them 
suitable back-up analogues for lead 5. 
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Trypanosoma brucei spp. parasites are the causative agents of the deadly infectious disease Human 
African Trypanosomiasis (HAT). This Neglected Tropical Disease (NTD) is spread via the bite of an 
infected tsetse fly (Glossina spp.), and incidence of HAT coincides with the natural habitat of this vector 
in sub-Saharan Africa. Infected individuals initially represent rather non-specific, flu-like symptoms (i.e. 
fever, general malaise) and are elicited by T. brucei parasites replicating in the haemolymphatic system 
(stage 1 disease). Therefore, misdiagnosis and underdiagnosis are common, leaving patients untreated 
and allowing the parasites to eventually invade the central nervous system (stage 2 disease) and cause 
alterations in behaviour, and in circadian rhythm. This explains the more commonly known name for 
HAT, ‘sleeping sickness’.1-2 The neurological phase progresses to coma and death unless effectively 
treated with chemotherapy. 
Current estimates put about 57 million people, spread over 36 countries, at risk of contracting HAT. 
Nevertheless, strenuous efforts of the WHO and Médecins sans Frontières regarding active case finding, 
treatment, and vector control have been successful to bring down the number of newly diagnosed cases 
per annum3 (2164 reported new cases in 20163, 1442 in 2017 and 977 in 2018 according to the WHO4). 
Additionally, the recent approval of oral fexinidazole for advanced sleeping sickness represents a beacon 
of hope for people living in afflicted areas and is a leap forward to reach the goal of the WHO to 
eliminate HAT by 2020.5 However, caution is warranted, as elimination was equally close in the 1960s. 
So-called cryptic reservoirs of parasites that might re-initiate infections in apparently HAT-free regions, 
have been suggested to be the underlying cause of this re-emergence.5-7 Furthermore, fexinidazole is 
only recommended for use in infections caused by T. b. gambiense, while treatment of infections with 
T. b. rhodesiense still requires the use of melarsoprol,8 an organo-arsenical, causing treatment-related 
mortality in 2.5 to 5 % of cases.9 Additionally, drug resistance can be readily induced against 
fexinidazole in vitro,10-11 and this compound shows cross-resistance with nifurtimox, another nitro-
imidazole employed in the nifurtimox-eflornithine combination therapy (NECT).11 Moreover, 
fexinidazole treatment is characterized by a high pill burden.12 Finally, the need for stage-determination 
has not been eliminated as fexinidazole treatment was found inferior to NECT in patient with severe 
meningoencephalitic compromise.12-13 Therefore, the need for continued research efforts into new 
chemical entities with antitrypanosomal activity remains, particularly as no vaccine is available or in 
development.1-2 
African trypanosomes, just like all other protozoan parasites, are known to be unable to biosynthesize 
the purine ring from amino acid precursors.14-15 Hence, they acquire host-assembled purines (either as 
purine nucleobases or purine nucleosides) to fulfil the demands of their replication and metabolism. To 
this end, they make use of multiple purine (nucleoside and/or nucleobase) transporters to actively 
salvage these metabolites,14 which are then employed by the enzymes of the purine salvage pathway. 
Purine salvage dependency represents a potentially fertile ground for the discovery of antitrypanosomal 
agents with a purine nucleoside scaffold. The potential utility of exploiting purine auxotrophy was 
realized as early as the 1960s, when Jim Williamson found that naturally occurring ‘nucleoside 
antibiotics’ such as tubercidin and cordycepin (Figure 1) displayed considerable trypanocidal efficacy.16-
17 
Recently, we have reported on the discovery of 7-substituted tubercidin analogues (e.g. 4, Figure 1) as 
potent and selective anti-T. brucei agents.18 Additionally, we discovered that the combination of the 3’-
deoxyribuforanose sugar of cordycepin with the 7-deazapurine base of tubercidin resulted in highly 
potent ‘hybrid’ compounds, of which 5 was able to cure CNS-stage T. b. brucei infections in mice by 
oral dosing, marking it a promising lead compound for further development.19 In the present study, we 
describe our efforts to systematically investigate the structure-activity-relationship (SAR) of these 3’-
deoxy-7-deazapurine nucleoside analogues and identify several potent and selective back-up derivatives 
that are ready for further evaluation in animal models of HAT. Furthermore, we provide in vitro data on 
resistant parasites cell lines. Finally, we generate insight into the transporter-mediated uptake of selected 
analogues into the trypanosome, resulting in a refinement of the recognition motif for the T. brucei P1 
adenosine transporter. 
 
Figure 1: Structures of purine nucleoside analogues and antitrypanosomal agents. Structures in the 
lower two boxes represent analogues prepared in this study; B, nucleobase. 
 
 
Results and discussion 
The preparation of nucleoside analogues is presented and discussed in the Supporting Information. The 
prepared nucleoside analogues were evaluated in vitro by drug sensitivity assays (Alamar Blue) against 
T. b. brucei and T. b. rhodesiense. Simultaneously, cytotoxicity was assayed by employing MRC-5SV2 
human fibroblast cells. The results of the in vitro evaluation are presented in Table 1 – 3.  
 
Table 1: In vitro antitrypanosomal activity of prepared nucleosides analogues. pEC50 values are depicted 
as average and SEM of 2–5 independent determinations. Values from different experiments were 
reported between brackets when an average could not be calculated.  
 
Cpd. R = 













T. b. rhod.) 
2  
cordycepin 
-- 6.77 ± 0.08 6.95 ± 0.16 <4.20 >370 >560 
3 
tubercidin 




519 H 7.32 ± 0.07 9.28 ± 0.03 <4.20 >1300 >120000 






























13 ≡-propyl 6.49 ± 0.21 7.45 ± 0.04 <4.20 >190 >1800 
14 ≡-butyl 6.49 ± 0.21 7.22 ± 0.16 <4.20 >190 >1050 








17 -ethyl 5.75 ± 0.07 6.19 ± 0.07 <4.20 >36 >98 








4.40 ± 0.05 4.44 ± 0.02 <4.20 >1.6 >1.8 
2120 c-hexyl <4.20 <4.20 <4.20 -- -- 











X = H 
H <4.20 <4.20 <4.20 -- -- 
25 
X = H 
Br <4.20 <4.20 <4.20 -- -- 
26 
X = OH 
H <4.20 <4.20 <4.20 -- -- 
Suramin -- 7.50 ± 0.12 7.50 ± 0.06 -- -- -- 
 
Building on the discovery of the highly potent nucleoside analogues 5 and 6,19 the SAR in the sugar as 
well as the heterocyclic moiety was thoroughly investigated by modifying virtually every position. First, 
the importance of the 7-substituent was probed (Table 1) by changing the nature of the halogen (7, 8 & 
9). This revealed that all of these halogenated analogues displayed highly potent in vitro 
antitrypanosomal activity (T. b. brucei pEC50 > 8.00), with only the iodide-substituted derivative 9 being 
slightly less potent than the others. All halogenated analogues did display some cytotoxicity against 
MRC-5 cells; nonetheless, each had an excellent selectivity index. Introduction of two potential halogen 
bio-isosters, CF3 (10) and SCF3 (11), led to a large drop in activity, particularly for the SCF3 substituted 
analogue. Next, we evaluated different carbon-based substituents, and found these, in general, to be less 
active than the 7-halogenated analogues. However, among these, small and linear substituents conferred 
the highest in vitro activity (12 and 16), with the ethynyl analogue giving similar activity as the 
halogenated compounds. Elongation of the carbon chain resulted in reduced potency (compare 12 with 
13, 14 and 15), albeit that the latter three still exhibited sub-micromolar EC50 values. Complete 
saturation (17) or elongation of the 7-vinyl substituent (18) equally resulted in the loss of in vitro activity, 
underscoring that a small unsaturated group is optimal, presumably for steric reasons. This is further 
evidenced by the cyclohexenyl analogue 20,20 which can be seen as a substituted vinyl analogue, 
displaying almost no antitrypanosomal activity at all. An aromatic ring immediately attached to the 7-
position of the purine ring (2220 and 23) resulted in analogues with supramicromolar potency. 
Additionally, none of our previously reported substituted 7-phenyl analogues, which displayed potent 
anti-Trypanosoma cruzi activity,20 surpassed the 1 µM anti-T. brucei activity mark (data not shown). 
Most remarkably, the 2-pyridine substituted derivative 23, for which the corresponding ribofuranose (4) 
emerged as the most potent analogue from our previous study,18 displayed substantially lower in vitro 
potency than 4, in sharp contrast to the effect observed upon 3’-deoxygenation of tubercidin (compare 
3 and 5). 
Lastly, L-nucleosides 24 and 25, which are enantiomers of 5 and 6 respectively, failed to elicit any 
antitrypanosomal activity, indicating the absolute requirement of the D-configuration for activity. This 
was also observed for L-tubercidin 27.  
Having identified that high in vitro potency is conferred by 7-halogens and small, linear carbon-based 
substituents, we turned our attention to other positions of the purine ring (C8, N6 and N1; Table 2). 
Based on previously discovered differences in trypanosomal nucleoside transporter substrate 
preferences,19 it was decided to create matched pairs to compare every modification for two 7-
substituents: 7-H and 7-Br. 
The introduction of a substituent (Br) in the 8-position of the purine ring (28) led to two orders of 
magnitude lower pEC50 (compare with 5), which indicates that a fixed syn-conformation of the 
nucleobase is detrimental for antitrypanosomal activity. Generally, methylation of the 6-amino group or 
substituting it for an OH (keto tautomer), OMe21, or SMe is not tolerated. Interestingly, removal of any 
functionality (analogue 40) gave rise to the most potent 6-amino modified analogue of 6. This is 
noteworthy as in the corresponding N7 purine analogues, 3’-deoxygenation resulted in weaker in vitro 
antitrypanosomal activity.22 Indeed, 7-bromide substituted nucleosides systematically displayed better 
in vitro activity than their 7-unsubstituted matched pairs. Lastly, the importance of the N1 nitrogen was 
investigated (compounds 41 and 42), from which it was learned that it is absolutely required for activity, 
which was also observed for the corresponding 6-chloride substituted derivatives (43 and 44).  
 
 
Table 2: In vitro antitrypanosomal activity of prepared nucleosides analogues. pEC50 values are depicted 
as average and SEM of 2–5 independent determinations. Suramin was used as a reference drug, of which 
the data are presented in Table 1. 
 
Cpd. X = R = 















519 H NH2 7.32 ± 0.07 9.28 ± 0.03 <4.20 >1300 >120000 




27 -- -- <4.20 <4.20 <4.20 -- -- 
28 -- -- 5.30 ± 0.19 5.99 ± 0.18 <4.20 >12 >62 
29 H NHMe 4.57 ± 0.02 4.82 ± 0.08 <4.20 >2 >4 
30 Br NHMe 5.21 ± 0.04 5.08 ± 0.01 <4.20 >10 >7 
31 H NMe2 <4.20 <4.20 <4.20 -- -- 
32 Br NMe2 5.73 ± 0.03 6.10 ± 0.15 <4.20 >34 >80 
33 H OH 4.53 ± 0.00 5.54 ± 0.10 <4.20 >2 >22 
34 Br OH 5.09 ± 0.00 5.65 ± 0.02 <4.20 >7 >28 
35 H -OMe <4.20 <4.20 <4.20 -- -- 




37 H SMe <4.20 4.24 ± 0.04 <4.20 -- -- 




39 H H 4.55 ± 0.02 4.64 ± 0.04 <4.20 >2 >2 




41 H NH2 <4.20 4.51 ± 0.02 <4.20 -- >2 
42 Br NH2 4.45 ± 0.02 <4.20 <4.20 1.8 -- 
43 H Cl 4.51 ± 0.02 5.10 ± 0.01 <4.20 >1.8 -- 





Next, we turned our focus towards modifying the sugar ring (Table 3). First, we explored the influence 
of the 2’-hydroxyl group by alkylating it (45 and 46), changing its relative orientation (from 3’-
deoxyribo to 3’-deoxyarabino, 47 and 48), and removing it (49, 50 and 51). Alkylation or removal led 
to an almost complete loss in activity. This is in line with the reported low antitrypanosomal potency of 
2,3-dideoxyadenosine,23 which we hypothesize, results from a lack of downstream activation rather than 
insufficient transporter-mediated uptake, as both the P1 and P2 transporters have at least equally good 
affinity for 2’-deoxyadenosine as for adenosine.24 The 3’-deoxyarabino epimer 48 did display 
submicromolar activity, although it remains roughly two orders of magnitude less potent than its 2’-
epimer 6. The loss of potency is in agreement with 2-fluorocordycepin, which lost its activity even more 
dramatically upon 2’-epimerization.22  
Then, we investigated the C5’ position of the ribofuranose. Removal (52 and 53) or methylation (54) of 
the 5’-OH strongly impacted the antitrypanosomal activity, and would be consistent with a requirement 
for adenosine kinase-mediated phosphorylation (as demonstrated for 519) at this position (i.e. the 
subversive substrate hypothesis15). The introduction of C5’-S-alkyl groups25 was also strongly 
detrimental to activity and resulted in only one analogue with low micromolar activity, 58, suggesting 
significant differences with the C5’-thioalkyl nucleoside series investigated by Cyrus Bacchi and co-
workers (e.g. HETA).25-27  
Finally, we also evaluated intermediates that feature a silyl group at the 2’-OH (61, 62) or 5’-OH (63). 
Analogue 62 in particular, was endowed with submicromolar antitrypanosomal activity (pEC50 = 6.20 
± 0.09 against T. b. brucei) and no cytotoxicity. The antitrypanosomal activity cannot be readily 
explained based on the SAR trends described above. This remaining protecting group as a specific 
nucleoside modification is reminiscent of certain antiviral nucleosides e.g. TSAO-T28-30 and reported 
Plasmodium falciparum dUTPAse inhibitors.31-32  
 
Table 3: In vitro antitrypanosomal activity of ribofuranose-modified analogues of 5 and 6. pEC50 values 
are depicted as average and SEM of 2–5 independent determinations. Values from different experiments 
are reported between brackets when an average could not be calculated. Suramin was used as a reference 
drug, of which the data are presented in Table 1. 
Cpd. Structure 

















7.32 ± 0.07 9.28 ± 0.03 <4.20 >1300 >120000 
619 
 




















5.18 ± 0.00 6.22 ± 0.01 <4.20 >9 >106 
48 
 























<4.20 <4.20 <4.20 -- -- 
53 
 

















4.58 ± 0.13 <4.20 -- >2.4 
57 
 












<4.20 <4.20 <4.20 -- -- 
60 
 
4.57 ± 0.00 5.25 ± 0.13 <4.20 >2 >11 
61 
 
<4.20 <4.20 <4.20 -- -- 
62 
 
6.20 ± 0.09 6.56 ± 0.20 <4.20 >102 >230 
63 
 





In summary, the thorough SAR investigation of lead molecule 5 presented above, shows narrow but also 
relatively unpredictable trends. Only position 7 of the purine ring tolerates other halogens or small and 
linear carbon-based substituents, with either no (halogens) or modest (e.g. substituted alkynyl) loss of 
in vitro antitrypanosomal activity. The sugar ring does not tolerate additional modification. Matched 
molecular pair analysis showed that, in general, modifications were more tolerated for the 7-Br 
substituted 7-deazapurines than for the 7-H analogues.  
 
Since nucleoside analogues inherently are polar molecules, uptake via passive diffusion is unlikely, and 
not consistent with documented resistance to nucleoside analogues in transporter mutants of various 
protozoa.14 As purines are essential nutrients for all protozoan parasites including T. brucei, they have 
evolved an array of efficient purine nucleoside and nucleobase transporters. Of particular relevance for 
purine nucleoside analogues are the P1 and P2 adenosine transporter systems in T. brucei.14, 24, 33 The P2 
transporter has a clear link to the development of (uptake-related) drug resistance, considering that its 
encoding gene (AT1)34 is single-copy and non-essential for parasite survival.35 Extensive investigation 
of this transporter showed that it is in fact a nucleobase transporter, with adenine being its preferred 
substrate, whilst tolerating the sugar moiety of adenosine. On a molecular level, this originates from the 
amidine recognition motif present as the N1-C6-NH2 aminopyrimidine element in adenine and 
adenosine,14, 24, 36-37 but also in the melamine part of melarsoprol and the benzamidine portion of 
pentamidine38, furamidine39, and diminazene40.  
Several nucleoside analogues have previously been shown to display cross-resistance with known 
trypanocides that also (partially) depend on the P2 transporter for internalization. This resistance profile 
has been reported for tubercidin and cordycepin,23 as well as for the recently reported analogue 5,19 
albeit that the latter still displays submicromolar in vitro activity against P2 transporter knock-out 
parasites.19 On the other hand, the P1 transporter is encoded by several closely related genes, and P1-
based resistance has never been reported.14, 41-42 In view of this, nucleoside analogues that are (also) 
substrates of P1 transporters can be expected to withstand resistance, at least at the level of compound 
accumulation, and not to show cross-resistance with any currently used trypanocides. We have thus 
evaluated several of the nucleoside analogues prepared in this study against a panel of drug resistant T. 
brucei cell lines (Table 4). Resistance of two of these is due wholly or in part to the removal of the P2 
transporter (TbAT1-KO and B48), both are to different degrees resistant to existing amidine-bearing 
drugs such as melarsoprol, pentamidine and diminazene. The B48 clone, which was developed from the 
TbAT1-KO cell line,43 has acquired additional resistance to pentamidine through the loss of the AQP2 
gene, which is the primary uptake mechanism of pentamidine.44 Drug sensitivity against ISRM1, an 
isometamidium-resistant cell line with considerable diamidine cross-resistance due to reduced 
mitochondrial membrane potential,45 was also determined. In all instances, a comparison to the parental 
cell line (Lister-427) was made, and a resistance factor (RF) was calculated. 
The TbAT1-KO cell line demonstrated an approximately 10-fold reduced drug sensitivity to 5.19 This 
concurs with the current substrate recognition model for the P1 transporter, which considers the 3’-OH, 
5’-OH, N7 and N3 of purine nucleosides as the key interaction elements.46 In line with this model, 
removal of two elements (in casu 3’-OH and N7) results in impaired binding to the P1 transporter, whilst 
maintaining excellent affinity for the P2 transporter, and thus explains the observed resistance profile 
for TbAT1-KO parasites.19 Interestingly, the addition of a halogen (Br in the case of 6) was able to 
mitigate this resistance profile by restoring affinity for P1. Therefore, we first investigated all other 7-
halogenated 3’-deoxy nucleoside analogues 7 (F), 8 (Cl) and 9 (I) in the AT1-KO cell lines. This revealed 
that, although a small shift in drug sensitivity was observed, it was much attenuated with regard to the 
parent 7-unsubstituted analogue 5, with a mere 3-fold shift rather than a RF >11. The same trend was 
observed for the B48 clone, indicating that these analogues, as expected, are not substrates for AQP2.  
Interestingly, this trend was even stronger for other 7-substituted (non-halogen) analogues, such as 
ethynyl (12), 2-phenylethynyl (15), vinyl (16) and phenyl (2220), with TbAT1-KO RF values ≤ 2.2. 
Although a limited decrease in activity could be noted against TbAT1-KO and B48 strains, this was 
much smaller than observed for 5, which has no 7-substituent. This is also in agreement with our 
previous findings for the 7-(pyridin-2-yl)-substituted ribofuranose analogue 418, which equally 
demonstrated reduced activity against P2-compromised strains (also vide infra). We also assessed the 
effects of N6-methylation (30 and 32) as well as N6 removal (40), and observed that these analogues 
are not subject to P2-conferred resistance, but if anything, tended to be somewhat more active against 
AT1-KO strains (P>0.05, unpaired Student t-test). This may be explained by compensatory upregulation 
of P1 transporter activity in the TbAT1-null trypanosomes,23, 47 an effect that has previously been 
observed for 2,6-N-disubstituted adenosine analogues.36, 48 Also, the antitrypanosomal activity of the 3’-
deoxyarabino analogue 48 proved to be independent of the P2 transporter and thus represents a suitable 




























Table 4: Evaluation of in vitro drug sensitivity of selected nucleoside analogues against resistant T. brucei cell lines. Depicted in the table are the pEC50 values, 
which represents the mean and SEM of at least three independent determinations. The resistance factor (RF) was calculated as the ratio of EC50 values from the 
resistant cell lines and the Lister-427 line. TbAT1-KO: T. brucei cell line lacking the TbAT1/P2 transporter gene. B48: TbAT1-KO derived clone, resistant to 
pentamidine, diminazene and melaminophenyl arsenical. ISMR1: isometamidium resistant cell line. Statistical difference between control (Lister-427) and 















7.48 ± 0.01 6.43 ± 0.01 11 6.43 ± 0.01 11 7.49 ± 0.05 0.97 
619 
 
8.75 ± 0.07 8.67 ± 0.05 1.2 8.88 ± 0.08 0.75 8.96 ± 0.06 0.63 
7 
 
8.57 ± 0.05 8.03 ± 0.02 3.5*** 7.85 ± 0.04 5.3** 8.33 ± 0.03 1.7* 
8 
 
9.11 ± 0.09 8.59 ± 0.07 3.3* 8.58 ± 0.05 3.4** 8.53 ± 0.07 3.8** 
9 
 
8.46 ± 0.14 7.88 ± 0.07 3.8** 8.02 ± 0.10 2.8 7.64 ± 0.03 6.7*** 
12 
 
7.94 ± 0.03 7.60 ± 0.03 2.2** 7.43 ± 0.03 3.2*** 7.64 ± 0.03 2.0** 
15 
 
6.16 ± 0.04 6.17 ± 0.00 0.97 6.02 ± 0.03 1.4* 6.05 ± 0.10 1.8* 
16 
 
7.13 ± 0.02 7.09 ± 0.02 1.2 6.93 ± 0.02 1.5** 6.98 ± 0.02 1.5** 
22 
 
5.66 ± 0.08 5.30 ± 0.07 2.2* 5.39 ± 0.11 1.8 5.33 ± 0.13 2.1 
30 
 
4.91 ± 0.07 5.19 ± 0.01 0.54 5.16 ± 0.02 0.57 4.90 ± 0.05 1.0 
32 
 
5.13 ± 0.07 5.31 ± 0.06 0.66 5.12 ± 0.01 1.0 5.49 ± 0.03 0.43* 
40 
 
6.39 ± 0.05 6.54 ± 0.02 0.7 6.68 ± 0.06 0.52* 6.45 ± 0.04 0.87 
48 
 
6.49 ± 0.03 6.52 ± 0.02 0.94 6.42 ± 0.03 1.3 6.53 ± 0.00 0.91 
62 
 
5.63 ± 0.01 5.66 ± 0.02 0.94 5.57 ± 0.01 1.2* 5.67 ± 0.01 0.92 
Pentamidine -- 7.98 ± 0.05 7.73 ± 0.04 1.8*** 6.00 ± 0.07 95*** 6.84 ± 0.10 14** 
Diminazene -- 6.37 ± 0.06 5.35 ± 0.08 11*** 5.15 ± 0.09 17*** 5.53 ± 0.06 6.9*** 
Isometamidium -- 6.19 ± 0.05 6.13 ± 0.07 1.2 6.25 ± 0.09 0.85 5.50 ± 0.06 4.8*** 
 
Based on the observation that the activity of several 7-substituted nucleoside analogues was only 
marginally affected by the removal of the P2 transporter (Table 4), we sought to gain further insight into 
the engagement of the purine transporters by performing competition experiments with [3H]-adenosine 
for three representative 7-substituted analogues, i.e. 7, 12 and 22 (Figure 2 and Table 5).  
 
 
Figure 2: Uptake of [3H]-adenosine via T. brucei P1 and P2 transporter systems in the presence of an 
increasing concentration of nucleoside analogues 7, 12 and 22. P1 transport is measured in B48 cells, 
which lack the P2 transporter. P2-mediated uptake is measured in B48 cells, stably overexpressing the 
P2 transporter protein. P2-transporter assays are performed in the presence of 100 µM inosine to block 
all P1-mediated uptake.37 Each panel depicts one representative example of three independent 
experiments, each performed in triplicate. Error bars depict SEM, and when not shown, fall within the 







Table 5: Kinetic parameters of selected nucleoside analogues for P1 and P2 transporters of bloodstream 
form T. brucei. Km (indicated in bold) and Ki values are stated in µM (± SEM, n ≥ 3). ΔG0 values are 
stated in kJ/mol. δ(ΔG0) was calculated with respect to the ΔG0 of the permeant adenosine, and is stated 
in kJ/mol. The values for 5 and 6 were taken from reference 19. 
Cpd. Structure 
P1 transporter P2 transporter 
Km or Ki ΔG




0.12 ± 0.02 -39.4 --  0.53 ± 0.02 -35.8 --  
519 
 
99.9 ± 21.7 -22.8 16.6 0.15 ± 0.03 -38.9 -3.1 
619 
 
9.47 ± 1.4 -28.7 10.7 0.50 ± 0.14 -35.9 -0.1 
7 
 
75.6 ± 5.6 -23.5 15.9 1.10 ± 0.1 -33.9 1.9 
12 
 
9.71 ± 0.41 -28.6 10.8 2.35 ± 0.13 -32.1 3.7 
22 
 
26.0 ± 7.1 -26.2 13.2 10.9 ± 0.9 -28.3 7.5 
26 
(L-tubercidin)  
N.E. -- -- 107 ± 3.4 -22.7 13.1 
 
None of the three nucleoside analogues had a profile similar to that of 5, which overwhelmingly 
depended on P2-mediated uptake with a P1/P2 Ki ratio of 670, explaining the RF of 11.2 for the TbAT1-
KO strain (Table 4). The 7-fluoro nucleoside analogue 7 did display comparable P1 binding affinity to 
6, but showed reduced P2 binding energy (Ki ratio 68.7; RF = 3.5), indicating an attenuation of P2-
dependent uptake, thus explaining the modest increase in EC50 for TbAT1-KO parasites (see Table 4). 
Remarkably, both 7-ethynyl and 7-phenyl analogues 12 and 22 displayed markedly better binding to the 
P1-transporter than tubercidin (Ki, tubercidin = 78 ± 6.4 µM for P124) and 5. This concurs with the very 
modest resistance factor observed for TbAT1-KO parasites for 12 and 22 (Table 4). We have previously 
observed a similar effect for analogue 4, featuring a 7-(pyridin-2-yl) group.18 Al together, these results 
allow the further refinement of the earlier model24 of the P1-transporter molecular recognition motifs. 
We demonstrate here that the loss associated with substituting N7 (presumed to engage in an H-bonding 
interaction with the P1 adenosine binding site) for CH, can be compensated for by the introduction of a 
halogen (with the exception of fluorine), a linear carbon chain or an aryl ring at C7. We hypothesize that 
the reason for the exception of the fluorinated analogue is because of its small size.  
Regarding transporter-dependent resistance, we found a strong correlation (Figure 3) between the RF 
values for TbAT1-KO and the ratio of the P1/P2 Ki values (r2=0.978; P=0.0014, F-test). On the other 
hand, the RF did not significantly correlate with the Ki for either transporter alone, although the 
correlation with the P1 Ki was much better than for P2 (r2=0.73/P=0.063 vs r2=0.12/P=0.56). 
 
 
Figure 3: Correlation plot between the Resistance Factor (RF) of compounds 5, 6, 7, 12, and 22 and 
their Ki for the P1 transporter (red line and symbols), the Ki for the P2 transporter (black line and 
symbols), and their ratio (P1/P2; blue line and symbols). 95% confidence intervals are indicated by 
dotted lines and correlation coefficient r2 is given for each line. 
 
Finally, we also determined the ability of L-7-deazaadenosine (26) to inhibit [3H]-adenosine uptake via 
the P1 and P2 transporter as the effect of enantiomeric nucleoside analogues for these T. brucei 
transporters has remained unexplored. The L-nucleoside 26 analogue was unable to affect the uptake of 
[3H]-adenosine via P1, which is expected as recognition of D-7-deazaadenosine occurs via elements in 
both the sugar as well as the purine ring part. The P2 transporter affinity (Ki = 107 ± 3 µM) was also 
much lower than previously reported for D-7-deazaadenosine, (Ki = 3.8 ± 0.7 µM24), indicating an 
unfavourable binding of the L-nucleoside with the transporter. These data are likely to be (part of) the 
reason for the inactivity of L-nucleosides against T. brucei. 
 
Selected nucleoside analogues (8, 9, 16 and 48) were then assayed for microsomal stability (Figure 4), 
to gain information on their potential for development as a therapeutic agent. Assays were run in the 
presence of either NADPH (mimicking phase I metabolism) or uridine glucuronyl transferase (UGT) 
enzymes (mimicking phase II metabolism). All four analogues were shown to be metabolically stable 
in both phase I and phase II metabolism mimicking experiments as virtually no reduction in percentage 
remaining parent compound could be observed.    
 
 
Figure 4: Analysis of metabolic stability in the presence of human liver microsomes for nucleoside 
analogues 8, 9, 16 and 48. Indicated is the percentage of parent compound remaining (y-axis) as a 
function of time. Filled symbols represent data from NADPH-fortified experiments (phase I 
metabolism), while open symbols represent data from UGT-enzyme added experiments (phase II 
metabolism). Fluconazole (stable in phase I assays) and diclofenac (susceptible to degradation in both 
phase I and phase II  assays) were added to assure proper functioning of the assay (data not shown). 
Data points are the mean from two independent experiments, and error bars are SD. When not shown, 
error bars fall withing the symbol. 
 
Conclusion 
In the present publication we have extensively studied the SAR of a series of 3’-deoxytubercidin 













































































































C Y P  -  N A D P H
U G T  e n z y m e s
N1, C6, C7 and C8 position of the purine ring, the C2’, C4’ and C5’ of the ribofuranose ring, and 
investigated the corresponding L-enantiomers of 5 and 6. This revealed that the 7-position was most 
tolerant for modification and that halogens or small (non-aromatic) carbon-based substituents (such as 
ethynyl) represent the most favourable substituents. Other modifications in the purine ring were much 
less tolerated. Investigation of modifications of the ribofuranose ring revealed that only the 3’-
deoxyarabino epimer 48 displayed submicromolar trypanocidal activity in vitro. An anti-conformation 
for nucleoside analogues and a D-ribofuranose stereochemistry appear to be an absolute requirement for 
adenosine transporter recognition and antitrypanosomal activity; although, as yet, this conclusion is 
based on a small sample size. Analysis of drug sensitivity against resistant T. brucei cell lines showed 
that the activity of several 7-substituted analogues was at most only modestly affected by the removal 
of the P2 transporter, representing an improvement over the previously discovered nucleoside analogue 
5. Detailed analysis of the binding affinity for the P1 transporter revealed that this transporter can 
accommodate a wide range of 7-substituted analogues, while N7 was previously reported to be a key 
recognition element for this transporter. Transporter-related resistance correlated best with the ratio of 
the Ki values for P1 and P2. Summarizing, this study has identified several 3’-deoxy nucleoside 
analogues that display potent antitrypanosomal activity and may overcome P2-related resistance in T. 
brucei. Several of these derivatives were found to be metabolically stable, providing confidence to 
translate the obtained data from this study into an in vivo setting. 
Methods 
Details on the chemical synthesis of discussed nucleoside analogues can be found in the Supporting 
Information. 
Drug sensitivity assays 
Standardised drug tests were performed on T. b. brucei Squib 427 (seeding density 1.5x104 
parasites/well) and T. b. rhodesiense strain STIB-900 (seeding density 4x103 parasites/well) at the 
University of Antwerp, Belgium, and on a panel of strains derived from T. b. brucei Lister-427 (seeding 
density 2x104 parasites/well) at the University of Glasgow, UK. The latter panel consisted of the multi-
drug resistant strains TbAT1-KO,35 B48,43 and ISMR145 (all at a seeding density of 2 x 104 parasites/well). 
Culturing and drug testing were performed exactly as described previously.18-19 All experiments were 
performed with bloodstream trypomastigotes, cultured in HMI-9 with 10% Fetal Bovine Serum (Gibco) 
at 37 ºC in a 5% CO2 incubator. Drug tests were performed on doubling dilutions of test compounds in 
96-well plates, incubated with 2×104 trypanosomes/well for 48 h before the addition of ‘Alamar blue’ 
solution (resazurin sodium salt; Sigma) and a further 24 h incubation. Fluorescence was read in a 
FLUOstar Optima (BMG Labtech, Aylesbury, Bucks, UK) and plotted to a sigmoid curve with variable 
slope (PRISM 7.0, GraphPad Software, San Diego, CA, USA) to obtain EC50 values (Effective 
Concentration 50%). Cytotoxicity against MRC-5SV2 fibroblasts was performed exactly as described 
previously.18, 20, 49 
Transport studies 
Transport of 50 nM 2,8-[3H]-adenosine (American Radiolabelled Chemicals, 40 Ci/mmol) was 
performed exactly as described previously, using a rapid oil-stop technique,50 where the incubation of 
107 cells with radiolabel and test compound is terminated by the addition of 1 mL ice-cold 250 µM 
unlabelled adenosine followed by immediate centrifugation through an oil layer. The cell pellet is 
harvested after flash freezing in liquid nitrogen, by cutting of the tip of the microfuge tube into a 
scintillation vial. Radioactivity was determined in a Hidex 300SL scintillation counter (Lablogic, 
Sheffield, UK). 
Metabolic stability 
Metabolic stability assays were performed with pooled human liver microsomes (Corning), which were 
stored at -80 °C until use. Solutions containing NADPH-generating system A and B (Corning) and UGT-
reaction mix A and B (Corning) were stored at -20 °C, until used in the assay. The test compounds 
(analogues 8, 9, 16 and 48) were dissolved in DMSO at a concentration of 10 mM, as well as the two 
reference compounds diclofenac and fluconazole (metabolic stability data for the reference analogues 
not shown). The assay protocol follows the BD Biosciences Guidelines for use (TF000017 Rev1.0), 
with only minor changes. Metabolic stability was assayed for either phase I metabolism (NADPH 
fortification) or for phase II metabolism (uridine diphosphate glucuronic acid, UDPGA fortification). 
For phase I metabolism mimicking assays, the test compound was incubated at 1 µM with 0.5 mg/mL 
liver microsomes in potassium phosphate buffer solution. The reaction was started by the addition of 1 
mM NADPH (t=0). At several times points (0, 15, 30 and 60 min), 20 µL samples were withdrawn, 
mixed with 80 µM ice-cold acetonitrile, containing tolbutamide as an internal standard. Then, the 
mixture was vortexed for 30 s, centrifuged at 4 °C for 5 min at 15 000 rpm. The supernatant was kept at 
-80 °C until the analysis by UPLC/MS-MS (see below). For phase II stability assays, compounds, at a 
concentration of 5 µM, were incubated with 0.5 mg/mL liver microsomes, and the reaction was started 
by adding 2 mM UDPGA cofactor to the mixture. Samples were taken in the same time schedule as 
described above for the phase I metabolic stability assays. The samples were then analysed by UPLC-
MS², employing a Waters Aquity UPLC module coupled to a tandem quadrupole (Waters Xevo), 
equipped with an electrospray (ESI) interface, operated in the multiple-reaction-monitoring (MRM) 
mode. Data are expressed as the percentage loss of the parent compound. Fifty percent remaining parent 





Schemes and discussion on the chemistry are presented in the Supporting Information. 
Experimental data of the prepared nucleoside analogues in this study can be found in the Supporting 
Information. 
Copies of 1H, 13C and 19F spectra of compounds 8-19, 23-26, 28-60, 70, 74, 75, 89 and 92 can be found 
in the Supporting Information. 1H-13C gHMBC of compounds 13, 14, 70, 74, 75, 89 and 92 as well as 
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